



(51) International Patent Classification:

A61K 31/506 (2006.01) A61P 37/00 (2006.01)
A61P 17/00 (2006.01)

(21) International Application Number:

PCT/CN2024/138717

(22) International Filing Date:

12 December 2024 (12.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202311735481.6 15 December 2023 (15.12.2023) CN
63/617,161 03 January 2024 (03.01.2024) US

(71) Applicant: **BEIJING INNOCARE PHARMA TECH CO., LTD.** [CN/CN]; Bldg. 8, Community No. 1, No. 8 Courtyard, Life Park Road, ZGC Life Science Park, Changping District, Beijing 102206 (CN).

(72) Inventors: **CUI, Jisong**; Bldg. 8, Community No. 1, No. 8 Courtyard, Life Park Road, ZGC Life Science Park, Changping District, Beijing 102206 (CN). **ZHOU, Wei**; Bldg. 8, Community No. 1, No. 8 Courtyard, Life Park Road,

ZGC Life Science Park, Changping District, Beijing 102206 (CN). **ZHANG, Bin**; Bldg. 8, Community No. 1, No. 8 Courtyard, Life Park Road, ZGC Life Science Park, Changping District, Beijing 102206 (CN). **ZHAO, Renbin**; Bldg. 8, Community No. 1, No. 8 Courtyard, Life Park Road, ZGC Life Science Park, Changping District, Beijing 102206 (CN).

(74) Agent: **SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC**; 435 Guiping Road, Xuhui District, Shanghai 200233 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHOD FOR TREATING ATOPIC DERMATITIS




FIG. 2

(57) Abstract: Provided herein is a method for treating atopic dermatitis by administering to a subject in need thereof Compound A, B, or C. Oral and topical are preferred routes of administration. In one embodiment, the subject is treated with about 50-150 mg/day of Compound A, B, or C by oral administration.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))